Olivier Colomban

Lyon, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications.

Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 21, 2026

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 13, 2026

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Journal: JCO precision oncology

Published: January 14, 2026

Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Journal: JCO oncology practice

Published: November 24, 2025

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Journal: Translational oncology

Published: September 29, 2025

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 25, 2025

Comparison of carboplatin doses according to several formulae in a cohort of patients treated for an ovarian cancer in real life.

Comparison of carboplatin doses according to several formulae in a cohort of patients treated for an ovarian cancer in real life.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 16, 2025

Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study.

Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 28, 2024

Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.

Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.

Journal: Gynecologic oncology

Published: September 11, 2024

KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.

KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.

Journal: Biomarkers in medicine

Published: June 17, 2024

Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.

Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.

Journal: JCO clinical cancer informatics

Published: February 16, 2024

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.

Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 26, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026